Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914602 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
A Phase 1 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00914602 is a Phase 1 study that has completed, run by XenoPort. The registered enrollment target is 14 participants.
The verdict
NCT00914602, a Phase 1 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation \[administered with Lodosyn® (carbidopa)\] and Sinemet® tablets in subjects with Parkinson's disease with Motor Fluctuations.
Interventions
- DRUG Sinemet 25-100 Oral Tablet
- DRUG XP21279
- DRUG Carbidopa Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914602
The ClinicalTrials.gov registry entry for NCT00914602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sinemet 25-100 Oral Tablet is the first listed.
NCT00914602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914602 about?
NCT00914602 is a clinical study titled "An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects". The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation \[administered with Lodosyn® (carbidopa)\] and Sinemet® tablets in subjects with Parkinson's disease with Motor Fluctuations.
What is the current status of trial NCT00914602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00914602?
The interventions under investigation include: Sinemet 25-100 Oral Tablet (DRUG), XP21279 (DRUG), Carbidopa Pill (DRUG).
Who is sponsoring clinical trial NCT00914602?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.